Survival for Glioblastoma Patients with Personalized Chemotherapy
Author Information
Author(s): Iwadate Y, Fujimoto S, Namba H, Yamaura A
Primary Institution: Chiba University Hospital and Chiba Cancer Center Hospital
Hypothesis
Can chemotherapy with optimized combinations of anticancer agents improve the survival of patients with glioblastoma multiforme?
Conclusion
The study found that individualized chemotherapy based on in vitro drug sensitivity testing can improve survival times for glioblastoma patients.
Supporting Evidence
- The median survival time for patients was 20.5 months.
- 26% of patients had a partial response to the individualized chemotherapy.
- 65% of patients achieved stable disease lasting more than 3 months.
Takeaway
Doctors tested different cancer medicines on patients' tumor cells to find the best treatment, which helped some patients live longer.
Methodology
A multi-institutional clinical trial was conducted where patients received chemotherapy selected based on in vitro drug sensitivity tests.
Potential Biases
Potential selection bias as patients without effective agents were treated with radiation alone.
Limitations
The study had a small sample size and lacked a control group for comparison.
Participant Demographics
Patients had a mean age of 51 years, with 24 males and 16 females.
Statistical Information
Confidence Interval
95% confidence interval for response rate.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website